David P. Bonita Purchases 83,611 Shares of Ikena Oncology, Inc. (NASDAQ:IMA) Stock

Key Points

• Director David P. Bonita purchased 83,611 shares of Ikena Oncology at an average price of $29.90, totaling nearly $2.5 million, which increased his ownership by 40.93% to 287,885 shares valued at approximately $8.6 million.
• Ikena Oncology recently reported an earnings per share (EPS) of ($0.06), outperforming analysts' expectations of ($0.14) for the quarter.
• Wedbush has lowered its target price for Ikena Oncology from $25.00 to $23.00, while maintaining a "neutral" rating on the stock.

Ikena Oncology, Inc. (NASDAQ:IMA - Get Free Report) Director David P. Bonita bought 83,611 shares of the stock in a transaction on Friday, July 25th. The shares were bought at an average price of $29.90 per share, for a total transaction of $2,499,968.90. Following the completion of the transaction, the director directly owned 287,885 shares of the company's stock, valued at $8,607,761.50. This trade represents a 40.93% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ikena Oncology Price Performance

IMA traded down $0.62 during trading hours on Friday, reaching $17.28. 11,207 shares of the stock traded hands, compared to its average volume of 45,097. The company has a market cap of $69.47 million, a price-to-earnings ratio of -2.25 and a beta of 0.51. Ikena Oncology, Inc. has a fifty-two week low of $11.65 and a fifty-two week high of $23.28. The firm's fifty day simple moving average is $15.97 and its two-hundred day simple moving average is $15.79.

Ikena Oncology (NASDAQ:IMA - Get Free Report) last posted its quarterly earnings results on Thursday, July 24th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.08. On average, research analysts predict that Ikena Oncology, Inc. will post -0.91 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Wedbush reduced their price target on shares of Ikena Oncology from $25.00 to $23.00 and set a "neutral" rating on the stock in a report on Friday, July 25th.

Hedge Funds Weigh In On Ikena Oncology

Several large investors have recently bought and sold shares of IMA. BNP Paribas Financial Markets purchased a new position in shares of Ikena Oncology in the fourth quarter worth approximately $72,000. XTX Topco Ltd increased its position in shares of Ikena Oncology by 350.6% in the first quarter. XTX Topco Ltd now owns 56,452 shares of the company's stock worth $72,000 after acquiring an additional 43,924 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Ikena Oncology during the fourth quarter worth approximately $72,000. Northern Trust Corp boosted its holdings in shares of Ikena Oncology by 19.7% during the fourth quarter. Northern Trust Corp now owns 57,565 shares of the company's stock worth $94,000 after purchasing an additional 9,456 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Ikena Oncology by 62.4% during the first quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company's stock worth $98,000 after purchasing an additional 29,369 shares during the period. Institutional investors and hedge funds own 75.00% of the company's stock.

About Ikena Oncology

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.